Immunotherapy Combinations for HNSCC – OncLive
OncLive |
Immunotherapy Combinations for HNSCC
OncLive Jared Weiss, MD: That one has the combination immunotherapy, though. The KESTREL trial has the EXTREME regimen, but it's 2:1:1 at least, so there's only a 1-in-4 chance of getting the EXTREME regimen. But it's EXTREME versus durvalumab alone … |
